We demonstrate that the MAPK pathway is critical for maintaining viability of HMBA-treated C6 cells and demonstrate synergy between HMBA and MEK inhibitors in vitro and in mouse xenograft experiments using C6 cells and human primary glioma sphere cultures. Here, MAP2K7 is linked to central nervous system cancer.